Highest-materiality recent filing
Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering
Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.
Prelude Therapeutics prices $90M public offering of common stock and pre-funded warrants
Offering of 18,018,014 common shares at $4.44/share and pre-funded warrants for 2,252,252 shares at $4.4399.
PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.
Dr. Morris, age 61, brings over 30 years of oncology drug development experience; most recently CMO at Lava Therapeutics.
Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396
Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.
FDA clears IND for Prelude's JAK2V617F inhibitor PRT12396; Phase 1 to start by Q2 2026
FDA cleared IND for PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms.
Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set
Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.
Prelude gets $60M from Incyte for JAK2V617F option; pauses SMARCA2; CMO resigns
Incyte receives exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program for $100M exercise price, plus up to $775M milestones and single-digit royalties.
Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732
Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.
Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026
Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.
Prelude Therapeutics receives Nasdaq bid price deficiency notice; has until Sep 23, 2025 to cure
Nasdaq notified Prelude on March 27, 2025 that its common stock closed below $1.00 for 30 consecutive business days.
Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026
Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.
Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program
PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).
Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers
Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.
Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept
Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.
3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.
Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024
Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.
Net loss $34.7M ($0.46/share) vs $30.4M ($0.54/share) in Q2 2023; R&D expense rose to $29.5M from $25.0M.
Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data
Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.
Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.
Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline
Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.
Prelude prioritizes SMARCA2 and CDK9, partners with AbCellera on ADCs, reports Q3 net loss $30.6M
Q3 net loss $30.6M ($0.45/share); cash at $230.5M; cash runway into 2026.
Prelude Therapeutics prices $100M public offering of common stock and pre-funded warrants
Offering of 3.05M voting shares and 1.45M non-voting shares at $5.75/share; pre-funded warrants for 12.9M shares at $5.7499 each.
Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024
Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.
Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development
Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.
Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.
Prelude Therapeutics EVP/Chief of Clinical Affairs Morosini resigns; advisor through May 5
Deborah Morosini resigned as EVP and Chief of Clinical Affairs effective April 6, 2022.
the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025
On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.
Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.
On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.
On April 6, 2022 (the “ Effective Date ”), Prelude Therapeutics Incorporated (the “ Company ”) and Deborah Morosini, the Company’s EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company
the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022
On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.
On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.
On September 16, 2021, Prelude Therapeutics Incorporated. (the “Company”) received notice from Christopher Pierce of his intention to resign as Executive Vice President and Chief of Business Operations of the Company effective on September 30, 2021, in order to pursue another employment opportunity.
the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021
Max materiality 0.80 · Median 0.60 · Most common event other_material